Blockade of the programmed death ligand 1 (PD-L1) as potential therapy for anaplastic thyroid cancer

被引：0
|
作者：
Silvia Cantara
Eugenio Bertelli
Rossella Occhini
Marì Regoli
Lucia Brilli
Furio Pacini
Maria Grazia Castagna
Paolo Toti
机构：
[1] University of Siena,Department of Medical, Surgical and Neurological Sciences
[2] University of Siena,Department of Molecular and Developmental Medicine
[3] Arezzo Hospital,Unit of Pathology
[4] University of Siena,undefined
来源：
Endocrine | 2019年 / 64卷
关键词：
PD-L1; PD-1; Anaplastic thyroid cancer; Immunotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：122 / 129
页数：7
相关论文
共 50 条
  • [21] Expression of programmed death-ligand 1 (PD-L1) in human pituitary neuroendocrine tumor
    Valentine Suteau
    Alexandre Collin
    Philippe Menei
    Patrice Rodien
    Marie-Christine Rousselet
    Claire Briet
    Cancer Immunology, Immunotherapy, 2020, 69 : 2053 - 2061
  • [22] Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis
    Berntsson, Jonna
    Eberhard, Jakob
    Nodin, Bjorn
    Leandersson, Karin
    Larsson, Anna H.
    Jirstrom, Karin
    ONCOIMMUNOLOGY, 2018, 7 (08):
  • [23] PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
    Bocanegra, Ana
    Fernandez-Hinojal, Gonzalo
    Zuazo-Ibarra, Miren
    Arasanz, Hugo
    Jesus Garcia-Granda, Maria
    Hernandez, Carlos
    Ibanez, Maria
    Hernandez-Marin, Berta
    Martinez-Aguillo, Maite
    Jose Lecumberri, Maria
    Fernandez de Lascoiti, Angela
    Teijeira, Lucia
    Morilla, Idoia
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07):
  • [24] Circulating Programmed Death Ligand-1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
    Vecchiarelli, S.
    D'Incecco, A.
    Minuti, G.
    Gallo, M.
    De Luca, A.
    Landi, L.
    Bennati, C.
    Spreafico, M.
    D'Arcangelo, M.
    Attilia, L.
    Mazza, V.
    Normanno, N.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2389 - S2389
  • [25] Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
    Shimoji, Masaki
    Shimizu, Shigeki
    Sato, Katsuaki
    Suda, Kenichi
    Kobayashi, Yoshihisa
    Tomizawa, Kenji
    Takemoto, Toshiki
    Mitsudomi, Tetsuya
    LUNG CANCER, 2016, 98 : 69 - 75
  • [26] Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer
    S. Muenst
    A. R. Schaerli
    F. Gao
    S. Däster
    E. Trella
    R. A. Droeser
    M. G. Muraro
    P. Zajac
    R. Zanetti
    W. E. Gillanders
    W. P. Weber
    S. D. Soysal
    Breast Cancer Research and Treatment, 2014, 146 : 15 - 24
  • [27] CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy
    Zwaenepoel, Karen
    Jacobs, Julie
    De Meulenaere, Astrid
    Silence, Karen
    Smits, Evelien
    Siozopoulou, Vasiliki
    Hauben, Esther
    Rolfo, Christian
    Rottey, Sylvie
    Pauwels, Patrick
    HISTOPATHOLOGY, 2017, 71 (03) : 357 - 365
  • [28] Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung
    Imanishi, Naoko
    Hirai, Ayako
    Yoneda, Kazue
    Shimajiri, Shohei
    Kuwata, Taiji
    Tashima, Yuko
    Takeuchi, Masahiro
    Iwai, Yoshiko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 117 (07) : 1563 - 1569
  • [29] Structural basis for small molecule targeting of the programmed death ligand 1 (PD-L1)
    Zak, Krzysztof M.
    Grudnik, Przemyslaw
    Guzik, Katarzyna
    Zieba, Bartosz J.
    Musielak, Bogdan
    Domling, Alexander
    Dubin, Grzegorz
    Holak, Tad A.
    ONCOTARGET, 2016, 7 (21) : 30323 - 30335
  • [30] Induction Mechanism of PD-L1 (Programmed Cell Death-ligand 1) in Sepsis
    Lee, Sang-Min
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2008, 65 (04) : 343 - 350
12345